<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2021.103018</article-id><article-id pub-id-type="publisher-id">PI-42588</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20210300000_26986451.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  幽门螺旋杆菌脲酶的性质及应用现状
  Properties and Application of 
  Helicobacter pylori Urease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卓</surname><given-names>越</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>建华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>中国药科大学生命科学与技术学院，江苏 南京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>11</day><month>05</month><year>2021</year></pub-date><volume>10</volume><issue>03</issue><fpage>138</fpage><lpage>141</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   幽门螺旋杆菌是一种与胃癌密切相关的细菌，它利用独特的适应机制，包括脲酶的催化活性，在大部分人的胃的酸性环境中生长。靶向脲酶是药物设计和根除幽门螺旋杆菌的关键策略。本文整理了脲酶与幽门螺旋杆菌危害之间的关联性，并对幽门螺旋杆菌脲酶的性质及其在幽门螺旋杆菌感染检测及治疗中的应用的最新进展进行综述。 Helicobacter pylori is a bacterium closely related to gastric cancer. It uses unique adaptive mechanisms, including catalytic activity of urease, to thrive in the acidic environment of the stomach of most people. Targeting urease is a key strategy for drug design and eradication of Helicobacter pylori. In this paper, the association between urease and the harm of Helicobacter pylori was summarized, and the properties of urease of Helicobacter pylori as well as its application and recent progress in the detection and treatment of Helicobacter pylori infection were reviewed. 
  
 
</p></abstract><kwd-group><kwd>幽门螺旋杆菌，脲酶，疫苗, Helicobacter pylori</kwd><kwd> Urease</kwd><kwd> Vaccine</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>幽门螺旋杆菌是一种与胃癌密切相关的细菌，它利用独特的适应机制，包括脲酶的催化活性，在大部分人的胃的酸性环境中生长。靶向脲酶是药物设计和根除幽门螺旋杆菌的关键策略。本文整理了脲酶与幽门螺旋杆菌危害之间的关联性，并对幽门螺旋杆菌脲酶的性质及其在幽门螺旋杆菌感染检测及治疗中的应用的最新进展进行综述。</p></sec><sec id="s2"><title>关键词</title><p>幽门螺旋杆菌，脲酶，疫苗</p></sec><sec id="s3"><title>Properties and Application of Helicobacter pylori Urease<sup> </sup></title><p>Yue Zhuo, Jianhua Chen<sup>*</sup></p><p>School of Life Science and Technology, China Pharmaceutical University, Nanjing Jiangsu</p><p><img src="//html.hanspub.org/file/9-1710270x4_hanspub.png" /></p><p>Received: Apr. 25<sup>th</sup>, 2021; accepted: May 19<sup>th</sup>, 2021; published: May 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/9-1710270x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Helicobacter pylori is a bacterium closely related to gastric cancer. It uses unique adaptive mechanisms, including catalytic activity of urease, to thrive in the acidic environment of the stomach of most people. Targeting urease is a key strategy for drug design and eradication of Helicobacter pylori. In this paper, the association between urease and the harm of Helicobacter pylori was summarized, and the properties of urease of Helicobacter pylori as well as its application and recent progress in the detection and treatment of Helicobacter pylori infection were reviewed.</p><p>Keywords:Helicobacter pylori, Urease, Vaccine</p><disp-formula id="hanspub.42588-formula69"><graphic xlink:href="//html.hanspub.org/file/9-1710270x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/9-1710270x8_hanspub.png" /> <img src="//html.hanspub.org/file/9-1710270x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>幽门螺旋杆菌(Helicobacter pylori)是一种主要定殖于胃上皮粘膜的革兰氏阴性菌，病理条件下也可在十二指肠中检测到。幽门螺旋杆菌最早于二十世纪80年代被发现，但直到澳大利亚内科医生Barry Marshall服用菌体感染胃溃疡后人们才开始重视起这种细菌的危害性，Marshall也因此发现获得了诺贝尔医学奖。现有研究表明，胃幽门螺旋杆菌是胃癌、胃溃疡和十二指肠溃疡的主要致病因子，全球每年可导致100多万人死亡 [<xref ref-type="bibr" rid="hanspub.42588-ref1">1</xref>]。幽门螺旋杆菌主要通过空泡毒素A (vacuolating cytotoxin A, vacA)和细胞毒素相关蛋白A (cytotoxin-associated gene A, cagA)发挥致病作用。VacA经菌体分泌排出后穿透胃上皮细胞，可在胞内产生大的酸性空泡，并通过刺激细胞的凋亡和坏死来促进细胞死亡 [<xref ref-type="bibr" rid="hanspub.42588-ref2">2</xref>]。CagA则是被细菌主动运输到人体细胞中，干扰肌动蛋白和细胞骨架的连接，并扰乱细胞周期调节的途径 [<xref ref-type="bibr" rid="hanspub.42588-ref3">3</xref>]。</p><p>脲酶是幽门螺旋杆菌能够在胃酸环境下生存的重要因子。脲酶对于幽门螺旋杆菌在胃部具有定殖作用，脲酶基因缺陷型的幽门螺旋杆菌不能够定殖在豚鼠胃粘膜上 [<xref ref-type="bibr" rid="hanspub.42588-ref4">4</xref>]。同时，脲酶能够分解消化道中的尿素，从而产生氨中和胃部的胃酸，改善幽门螺旋杆菌的生存环境。大量繁殖的幽门螺旋杆菌会在局部剧烈升高pH，损害人体内正常细胞质子泵、细胞表面受体的机能 [<xref ref-type="bibr" rid="hanspub.42588-ref5">5</xref>]。尿素分解产生的氨与水产生氢氧化物，直接对组织造成损伤。脲酶还能和致病因子VagA产生协同作用，诱发空泡产生的频率和大小，加重细胞的损伤程度 [<xref ref-type="bibr" rid="hanspub.42588-ref6">6</xref>]。</p></sec><sec id="s6"><title>2. 幽门螺旋杆菌脲酶的性质</title><p>幽门螺旋杆菌的脲酶由基因组中的脲酶基因簇编码，脲酶基因簇包含7个基因，分别为ureA、ureB、ureI、ureE、ureF、ureG和ureD [<xref ref-type="bibr" rid="hanspub.42588-ref7">7</xref>]。其中ureA和ureB是结构基因，分别编码脲酶的α亚基和β亚基。ureI编码特异性的尿素通道蛋白，协助脲酶通过胞质膜转运。而ureE、ureF、ureG和ureD则为辅助基因，与脲酶结合金属离子，发挥分解尿素能力有关。</p><p>幽门螺旋杆菌脲酶是由α (约26.7 kDa)和β (约60.1 kDa)两种亚基形成的六聚体蛋白，其结构为([αβ]3) 2 [<xref ref-type="bibr" rid="hanspub.42588-ref8">8</xref>]。其Km值约为0.2~0.8 mM，等点电在pH 6.0左右，最佳反应pH为8.0 [<xref ref-type="bibr" rid="hanspub.42588-ref9">9</xref>]。</p><p>从上个世纪90年代开始就有学者开始研究幽门螺旋杆菌脲酶的重组构建。LI TAIHU等在不含氨基酸的培养基中培养含有重组幽门螺旋杆菌脲酶基因的SE5000大肠杆菌，添加0.75 Μm NiCl<sub>2</sub>，脲酶结构基因过表达为完整的脲酶(pHP808)，在此条件下，表达的脲酶活性可达87 U/mg [<xref ref-type="bibr" rid="hanspub.42588-ref10">10</xref>]。VALERIE CUSSAC等在限制氮源供给的条件下培养重组幽门螺旋杆菌脲酶基因的大肠杆菌，表达的脲酶每毫克每分钟能水解0.83 &#177; 0.39 μmol尿素 [<xref ref-type="bibr" rid="hanspub.42588-ref11">11</xref>]。</p></sec><sec id="s7"><title>3. 幽门螺旋杆菌脲酶的应用</title><sec id="s7_1"><title>3.1. 幽门螺旋杆菌的检测</title><p>根据脲酶分解尿素产生氨的特点，在临床实践中，医务人员采用胃镜取样的侵入性方法检测患者的幽门螺旋杆菌感染状况。根据幽门螺旋杆菌常分布于胃部浅表和凹型上皮的特点，在治疗前的诊断中，取幽门2 cm处的远端窦部组织进行活检。活检组织使用相应的试剂盒进行体外检测，结果分析快速且成本低廉 [<xref ref-type="bibr" rid="hanspub.42588-ref12">12</xref>]。在一项关于快速尿素酶检测试剂盒检测准确性的研究当中，研究人员招募了150名志愿者，使用了组织学检验和PCR的方法对结果进行校正 [<xref ref-type="bibr" rid="hanspub.42588-ref13">13</xref>]。结果表明，不同品牌的检测试剂盒之间差异性小，反应结果稳定，并且对于使用质子泵抑制剂和抗生素的患者，快速尿素酶试剂盒对幽门螺旋杆菌感染的检测似乎比组织学检测更加敏感。因此相对于昂贵费时的组织学检验来说，如果没有其他组织学问题，试剂盒是一个十分可靠的选择。</p><p>幽门螺旋杆菌的检测除了侵入性的方法外，还有许多非侵入性的方法，其中的尿素呼气试验，因其操作简便，依从性好的特点而适用于儿童和妇女的感染检测 [<xref ref-type="bibr" rid="hanspub.42588-ref14">14</xref>]。检测原理同样也是利用了脲酶分解尿素的性质，以尿素为底物，标记碳同位素，制成胶囊，病人服下后，通过测定和定量呼出二氧化碳中标记的同位素碳来诊断幽门螺旋杆菌感染 [<xref ref-type="bibr" rid="hanspub.42588-ref15">15</xref>]。该试验通常使用两种碳同位素非放射性的<sup>13</sup>C和微量放射性的<sup>14</sup>C，它们的性能相差不大，敏感性和特异性均在90%以上。</p></sec><sec id="s7_2"><title>3.2. 幽门螺旋杆菌疫苗</title><p>目前临床上治疗幽门螺旋杆菌感染的主流方法是使用“铋剂 + 抗生素”的联合疗法，但铋剂的使用具有一定的副作用，因此必须得到有效监管 [<xref ref-type="bibr" rid="hanspub.42588-ref16">16</xref>]。随着幽门螺旋杆菌对各类抗生素耐药性不断增加，幽门螺旋杆菌疫苗的研发迫在眉睫，其中最受关注的当属幽门螺旋杆菌亚单位疫苗，针对幽门螺旋杆菌生长繁殖重要的相关蛋白设计重组蛋白抗原表达，诱导人体产生相应抗体，从而有效预防幽门螺旋杆菌感染。</p><p>在最新的一项研究中，研究人员通过将嗜中性粒细胞激活蛋白、脲酶亚单位α和亚单位β三种常用的幽门螺旋杆菌抗原搭配大肠杆菌的粘膜佐剂，在幽门螺旋杆菌感染小鼠模型上评价其免疫原性和治疗效果。结果显示口服幽门螺旋杆菌感染小鼠的胃细菌定殖显著减少。细菌负荷的减少伴随着血清抗原特异性IgG反应和粘膜IgA反应的显著增加(p &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.42588-ref17">17</xref>]。同时各种抗原表位也可联合发挥作用，一种新型的多价疫苗LHUC即由幽门螺旋杆菌粘附素(HpaA)、脲酶β亚基和过氧化氢酶抗原表位组成，在应用于治疗C57BL/6小鼠胃幽门螺旋杆菌感染模型时发现，LHUC诱导小鼠产生特异性IgG和IgA抗体，IgG抗体在体外显著抑制幽门螺旋杆菌脲酶和过氧化氢酶活性。此外，LHUC可以激活体内Th1、Th2和Th17混合T细胞免疫应答 [<xref ref-type="bibr" rid="hanspub.42588-ref18">18</xref>]。大量的动物实验已经为幽门螺旋杆菌疫苗的有效性提供了证据。同样在人体临床实验中，疫苗也显示出了不俗的效果。中国在2004年至2005年间，针对一种由幽门螺旋杆菌脲酶β亚单位与大肠杆菌耐热毒素融合而成的口服疫苗，对超过4000名儿童进行了疫苗的随机、双盲、安慰剂对照的3期临床实验，并在之后的三年间保持观察，结果显示疫苗的保护有效率达到了71.8% [<xref ref-type="bibr" rid="hanspub.42588-ref19">19</xref>]。疫苗接种现在可能成为一种有效的策略，显著减少全世界儿童的幽门螺旋杆菌相关疾病 [<xref ref-type="bibr" rid="hanspub.42588-ref20">20</xref>]。</p></sec></sec><sec id="s8"><title>4. 总结与展望</title><p>存在于幽门螺旋杆菌表面的脲酶对于抵抗人体胃酸环境十分必要，脲酶可以分解尿素产生氨，从而给幽门螺旋杆菌营造合适的生长pH。因此可以针对幽门螺旋杆菌的这一特点，合理的设计并寻找方案对幽门螺旋杆菌进行检测和治疗。抗生素在初期对于幽门螺旋杆菌的感染治疗取得了不错的效果，但随着使用频率的增加，抗生素治疗效果明显下降。疫苗作为新兴的幽门螺旋杆菌感染治疗手段已在临床上显现优势，但仍然需要在疫苗的安全性和长期有效性等问题上进行新的探索。</p></sec><sec id="s9"><title>文章引用</title><p>卓 越,陈建华. 幽门螺旋杆菌脲酶的性质及应用现状Properties and Application of Helicobacter pylori Urease[J]. 药物资讯, 2021, 10(03): 138-141. https://doi.org/10.12677/PI.2021.103018</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42588-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Devi, T.B., Devadas, K., George, M., Gandhimathi, A., Chouhan, D., Retnakumar, R.J., et al. (2021) Low Bifidobacte-rium Abundance in the Lower Gut Microbiota Is Associated with Helicobacter pylori-Related Gastric Ulcer and Gastric Cancer. Front Microbiol, 12, Article ID: 631140. &lt;br&gt;https://doi.org/10.3389/fmicb.2021.631140</mixed-citation></ref><ref id="hanspub.42588-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Isomoto, H., Moss, J. and Hirayama, T. (2010) Pleiotropic Actions of Helicobacter Pylori Vacuolating Cytotoxin, VacA. The Tohoku Journal of Experimental Medicine, 220, 3-14. &lt;br&gt;https://doi.org/10.1620/tjem.220.3</mixed-citation></ref><ref id="hanspub.42588-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hatakeyama, M. (2014) Helicobacter pylori CagA and Gastric Cancer: A Paradigm for Hit-and-Run Carcinogenesis. Cell Host Microbe, 15, 306-316. &lt;br&gt;https://doi.org/10.1016/j.chom.2014.02.008</mixed-citation></ref><ref id="hanspub.42588-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Tsuda, M., Karita, M., Morshed, M.G., Okita, K. and Nakazawa, T. (1994) A Urease-Negative Mutant of Helicobacter pylori Constructed by Allelic Exchange Mutagenesis Lacks the Ability to Colonize the Nude Mouse Stomach. Infection and Immunity, 62, 3586-3589. &lt;br&gt;https://doi.org/10.1128/IAI.62.8.3586-3589.1994</mixed-citation></ref><ref id="hanspub.42588-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">谷贵章, 宋达峰, 顾青. 幽门螺杆菌尿素酶的分子特性[J]. 药物生物技术, 2007, 14(4): 291-296.</mixed-citation></ref><ref id="hanspub.42588-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Montecucco, C., Papini, E., de Bernard, M. and Zoratti, M. (1999) Molecular and Cellular Activities of Helicobacter pylori Pathogenic Factors. FEBS Letters, 452, 16-21. &lt;br&gt;https://doi.org/10.1016/S0014-5793(99)00652-3</mixed-citation></ref><ref id="hanspub.42588-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">盛涛, 张建中. 幽门螺杆菌尿素酶研究现状[J]. 世界华人消化杂志, 1999, 7(10): 881-884.</mixed-citation></ref><ref id="hanspub.42588-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kappaun, K., Piovesan, A.R., Carlini, C.R. and Ligabue-Braun, R. (2018) Ureases: Historical Aspects, Catalytic, and Non-Catalytic Properties—A Review. Journal of Advanced Research, 13, 3-17.  
&lt;br&gt;https://doi.org/10.1016/j.jare.2018.05.010</mixed-citation></ref><ref id="hanspub.42588-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Krajewska, B. (2009) Ureases I. Functional, Catalytic and Kinetic Properties: A Review. Journal of Molecular Catalysis B: Enzymatic, 59, 9-21. &lt;br&gt;https://doi.org/10.1016/j.molcatb.2009.01.003</mixed-citation></ref><ref id="hanspub.42588-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hu, L.T. (1992) Helicobacter pylori Urease: Purification, Mo-lecular Cloning, and Enzymatic Activation in Escherichia coli. Microbiology Ph.D. Thesis, University of Maryland, Bal-timore.</mixed-citation></ref><ref id="hanspub.42588-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Cussac, V., Ferrero, R.L. and Labigne, A. (1992) Expression of Helicobacter pylori Urease Genes in Escherichia coli Grown under Nitrogen-Limiting Conditions. Journal of Bacteriology, 174, 2466-2473.  
&lt;br&gt;https://doi.org/10.3389/fmicb.2021.631140</mixed-citation></ref><ref id="hanspub.42588-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Pajares-García, J.M. (1998) Diagnosis of Helicobacter pylori: Invasive Methods. Italian Journal of Gastroenterology and Hepatology, 3, S320-S323.</mixed-citation></ref><ref id="hanspub.42588-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Dechant, F.X., Dechant, R., Kandulski, A., Selgrad, M., Weber, F., Reischl, U., Wilczek, W., Mueller, M. and Weigand, K. (2020) Accuracy of Dif-ferent Rapid Urease Tests in Comparison with Histopathology in Patients with Endoscopic Signs of Gastritis. Digestion, 101, 184-190. &lt;br&gt;https://doi.org/10.1159/000497810</mixed-citation></ref><ref id="hanspub.42588-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">曾妙, 杨三三, 李雪诺, 陈安海. 幽门螺旋杆菌的检测方法研究现状[J]. 海南医学, 2020, 31(6): 784-788.</mixed-citation></ref><ref id="hanspub.42588-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Sankararaman, S. and Moosavi, L. (2021) Urea Breath Test. StatPearls Publishing, Treasure Island.</mixed-citation></ref><ref id="hanspub.42588-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">崔璨璨, 李长锋, 张斌. 幽门螺旋杆菌感染治疗方案的研究现状和进展[J]. 吉林大学学报(医学版), 2017, 43(6): 1287-1290.</mixed-citation></ref><ref id="hanspub.42588-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Liu, M., Zhong, Y., Chen, J., Liu, Y., Tang, C., Wang, X., et al. (2020) Oral Immunization of Mice with a Multivalent Therapeutic Subunit Vaccine Protects against Helicobac-ter pylori Infection. Vaccine, 38, 3031-3041. 
&lt;br&gt;https://doi.org/10.1016/j.vaccine.2020.02.036</mixed-citation></ref><ref id="hanspub.42588-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Xie, W., Zhao, W., Zou, Z., Kong, L. and Yang, L. (2021) Oral Multivalent Epitope Vaccine, Based on UreB, HpaA, CAT, and LTB, for Prevention and Treatment of Helicobacter py-lori Infection in C57BL/6 Mice. Helicobacter, 12, Article ID: e12807. &lt;br&gt;https://doi.org/10.1111/hel.12807</mixed-citation></ref><ref id="hanspub.42588-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Zeng, M., Mao, X.H., Li, J.X., Tong, W.D., Wang, B., Zhang, Y.J., Guo, G., et al. (2015) Efficacy, Safety, and Immunogenic-ity of an Oral Recombinant Helicobacter pylori Vaccine in Children in China: A Randomised, Double-Blind, Place-bo-Controlled, Phase 3 Trial. Lancet, 386, 1457-1464. &lt;br&gt;https://doi.org/10.1016/S0140-6736(15)60310-5</mixed-citation></ref><ref id="hanspub.42588-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Blanchard, T.G. and Czinn, SJ. (2017) Identification of Hel-icobacter pylori and the Evolution of an Efficacious Childhood Vaccine to Protect against Gastritis and Peptic Ulcer Dis-ease. Pediatric Research, 81, 170-176. 
&lt;br&gt;https://doi.org/10.1038/pr.2016.199</mixed-citation></ref></ref-list></back></article>